Eli Lilly's oral weight loss drug Orforglipron clinical trial data missed expectations, causing stock price to plummet

Eli Lilly announced that the clinical trial data of the oral weight loss drug Orforglipron failed to meet market expectations, and the stock price fell nearly 14%. Shares of rival Novo Nordisk rose 6% as the market focused on competition in the GLP-1 obesity drug market.

Latest News

08-08
不敌司美格鲁肽！礼来口服新药减重效果不及预期股价暴跌15%
不敌司美格鲁肽！礼来口服新药减重效果不及预期股价暴跌15%
08-08
礼来第二季度营收155.6亿美元，口服减重药临床数据未达预期
礼来第二季度营收155.6亿美元，口服减重药临床数据未达预期
08-07
美股突发！减肥药巨头礼来跌超14%，半导体多数走强
美股突发！减肥药巨头礼来跌超14%，半导体多数走强
08-07
Stock Track | Eli Lilly Plummets 14.63% as Oral Weight Loss Drug Falls Short of Expectations Despite Strong Q2 Results
Stock Track | Eli Lilly Plummets 14.63% as Oral Weight Loss Drug Falls Short of Expectations Despite Strong Q2 Results
08-07
异动解读 | 礼来股价大跌14%，口服减肥药试验结果不及预期
异动解读 | 礼来股价大跌14%，口服减肥药试验结果不及预期
08-07
美股异动 | 诺和诺德(NVO.US)涨近6% 因竞争对手礼来(LLY.US)口服减肥药效果不及预期
美股异动 | 诺和诺德(NVO.US)涨近6% 因竞争对手礼来(LLY.US)口服减肥药效果不及预期
08-07
美股异动 | 诺和诺德(NVO.US)涨近6% 因竞争对手礼来(LLY.US)口服减肥药效果不及预期
美股异动 | 诺和诺德(NVO.US)涨近6% 因竞争对手礼来(LLY.US)口服减肥药效果不及预期
08-07
Eli Lilly Drops as Trial Data for Oral Obesity Drug Weigh on Q2 Results
Eli Lilly Drops as Trial Data for Oral Obesity Drug Weigh on Q2 Results
08-07
BUZZ-Lilly falls after oral weight-loss drug data fails to impress
BUZZ-Lilly falls after oral weight-loss drug data fails to impress
08-07
美股异动 | 礼来(LLY.US)大跌近14% 口服减肥药疗效不及预期
美股异动 | 礼来(LLY.US)大跌近14% 口服减肥药疗效不及预期
08-07
礼来口服药物Orforglipron平均减重仅11.2%，不及市场预期
礼来口服药物Orforglipron平均减重仅11.2%，不及市场预期
08-07
礼来：口服减肥药减重近12%，股价盘前跳水逾13%
礼来：口服减肥药减重近12%，股价盘前跳水逾13%
08-07
礼来(LLY)实验性减肥药试验数据不及预期盘前跌7.69% 竞争对手诺和诺德(NVO)涨8.46%
礼来(LLY)实验性减肥药试验数据不及预期盘前跌7.69% 竞争对手诺和诺德(NVO)涨8.46%
08-07
Eli Lilly Plunges 12% in Pre-Market Despite 38% Q2 Revenue Surge and Raised Guidance as Oral Weight-Loss Drug Falls Short of Expectations
Eli Lilly Plunges 12% in Pre-Market Despite 38% Q2 Revenue Surge and Raised Guidance as Oral Weight-Loss Drug Falls Short of Expectations
08-07
Eli Lilly's Oral Weight Loss Drug Falls Short of Expectations; Strong Q2 Results Unable to Prevent Stock Decline as Novo-Nordisk A/S Benefits
Eli Lilly's Oral Weight Loss Drug Falls Short of Expectations; Strong Q2 Results Unable to Prevent Stock Decline as Novo-Nordisk A/S Benefits
08-07
礼来(LLY.US)口服减肥药疗效不及预期 亮眼二季报难救股价大跌 诺和诺德(NVO.US)借势大涨
礼来(LLY.US)口服减肥药疗效不及预期 亮眼二季报难救股价大跌 诺和诺德(NVO.US)借势大涨
08-07
礼来(LLY.US)口服减肥药疗效不及预期 亮眼二季报难救股价大跌 诺和诺德(NVO.US)借势大涨
礼来(LLY.US)口服减肥药疗效不及预期 亮眼二季报难救股价大跌 诺和诺德(NVO.US)借势大涨
08-07
盘前重挫12%！礼来Q2营收大增38%并上调全年指引，但口服减肥药效果不及预期
盘前重挫12%！礼来Q2营收大增38%并上调全年指引，但口服减肥药效果不及预期
08-07
礼来股价在口服减肥药试验数据公布后暴跌
礼来股价在口服减肥药试验数据公布后暴跌
08-07
礼来股价跌幅扩大盘前最新下跌12.8%。
礼来股价跌幅扩大盘前最新下跌12.8%。
08-07
实验显示礼来口服药物Orforglipron平均减重11.2%低于预期
实验显示礼来口服药物Orforglipron平均减重11.2%低于预期
08-07
礼来美股盘前重挫11%。
礼来美股盘前重挫11%。
08-07
异动解读 | 礼来股价盘前大跌5.54%，投资者关注二季度财报及GLP-1市场竞争
异动解读 | 礼来股价盘前大跌5.54%，投资者关注二季度财报及GLP-1市场竞争
08-07
礼来美股盘前跌幅扩大至6%。
礼来美股盘前跌幅扩大至6%。
08-07
礼来美股盘前直线跳水现跌超3%。
礼来美股盘前直线跳水现跌超3%。

User Discussion

avatarJIANG_LIM
08-08
$Eli Lilly(LLY)$   Eli Lilly lost over $100 billion in one day. The reason? Their new obesity pill only helped people lose about 11 percent of their weight, which was far below what the market expected. The stock dropped 14 percent, but here’s the crazy part: it is still trading at over 50 times earnings. This is not just a bad day. It could be a shift in how investors value the company. Lilly was priced like every drug would be a blockbuster. But now one of their biggest launches underdelivered. That breaks the story. Yes, the company is solid. But the stock was priced for perfection, and that just got proven wrong. If investors start revaluing based on actual results, this may not be the bottom yet.
126